NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies, reported ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Melvin Mann, diagnosed with chronic myeloid leukemia in 1994, participated in a clinical trial for Imatinib that extended his ...

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

If Maggie O'Neil can't find a match among family members, she'll have to turn to a global nonprofit that connects volunteer ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

Introduction: A unique feature of chronic lymphocytic leukemia (CLL) is the increased number of circulating T cells preventing malignant B cells from undergoing apoptosis. Dysregulated expression of ...

The trial is focused on assessing TCB008’s effectiveness and tolerability in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS/AML) with refractory or relapsed ...